N/A N=51 Marijuana Use, Strength Training, and Alcohol Consumption (MUSTAC) Study
Chronic Pain
Primary: Alcohol Demand: Breakpoint — -6.00; -2.07; -1.81; -1.09 dollars/drink — p=.26
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Comparing the Effects of Upper and Lower Body Resistance Training on Pain Sensitivity
Healthy
Primary: Lower Body Resistance Exercise — 594.10; 572.54 kilopascals
Phase 3 N=205 Topical Ibuprofen for Delayed Onset Mulscle Soreness
Pain
Primary: Change From Baseline in the Time-Weighted Sum of Muscle Soreness With Movement Over 0-24 Hours Post-Dose 1 (MSM 0-24 ) — 22.2; 17.8; 29.7 units on a scale — p=0.200
N/A N=40 Mirthful Laughter and Muscle Soreness / Pain
Pain
Primary: Peak Force of Pain Tolerance Measurement — 2; 21 N
N/A N=60 The Effects of Intensity on Exercise-Induced Hypoalgesia During a Knee Extension Exercise
Healthy
Primary: Pressure Pain Threshold — 19.11; 48.22; -4.14 kilopascals
N/A N=34 Acetaminophen and Impaired Musculoskeletal Adaptations to Exercise Training
Sarcopenia · Osteoporosis · Aging
Primary: Change in Total Body Fat-free Mass — 1.5; 2.3; 0.7 kg — p=0.38
N/A N=42 Quantifying Myofascial Dysfunction in Post-Stroke Pain
Myofascial Dysfunction
Primary: T1 Rho MRI Relaxation Time of Shoulder External Rotator (Milliseconds) — 29.09; 27.15 milliseconds
N/A N=54 Impact of Exercise Training on Pain and Brain Function in Gulf War Veterans
Chronic Musculoskeletal Pain
Primary: Short Form McGill Pain Questionnaire Visual Analog Scale (VAS). — 29.82; 37.08; 30.07; 31.46 units on a scale — p=0.680
N/A N=41 Exercise Dosing for Pain in Healthy Participants
Pain
Primary: Intervention Effects on Mechanical Sensitivity Threshold — 125.6; 93.56; 63.04; 70.27 100*Value at 24 hours/Value at Baseline
N/A N=30 Pain Modulatory Profiles in Stretching
Healthy
Primary: Change in Pressure Pain Threshold — 317.27; 286.73; 304.69 kilopascals
Phase 2 N=34 Efficacy of a Controlled Short-term Trial of Cannabidiol (CBD) Ingestion on Reducing Symptomatic Response and Facilitating Recovery After Induced Muscle Injury
Muscle Injury · Recovery · Pain Relief
Primary: Self-report Ratings of Muscle Soreness — 0.0; 0.0 score on a scale
N/A N=30 Cervical Activation During Elastic and Manual Resistance
Cervical Pain
Primary: Percent of Peak Activation (%PA) — 51.72; 61.20; 88.1; 80.80 Percentage of Peak Activation (%PA)
N/A N=44 Mechanisms Underlying Local and Systemic Effects of Massage
Muscle Atrophy
Primary: Percent Change in Myofiber Cross Sectional Area (CSA). — -15.1; -13.4 percent change from baseline
N/A N=79 Exploratory Efficacy Study of Guaifenesin in Upper Back Pain
Upper Back Pain
Primary: Mean Change From Baseline of Both AM and PM Spasm Assessment Scores — 1.66; 1.87; 1.91; 1.54 Score on a Scale — p=0.68
N/A N=20 Cramer Sports Motion Tape and Low Back Pain EMG
Low Back Pain
Primary: Percent of Maximal Voluntary Isometric Contraction (%MVIC) — 226.41; 250.51; 162.47; 205.82 % of Max Voluntary Isometric Contraction
Phase 3 N=102 A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness
Muscle Soreness
Primary: Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW. — 50.15; 54.83 units on a scale (NRS)
N/A N=8 7 Tesla MRI Study in Patients With Statin Related Muscle Complaints
Statin-related Muscle Pain · Muscle Aches · Muscle Weakness
Primary: Change in Pre- and Post-phosphocreatine Relaxation Time — 5.58; 5.083 milliseconds
Phase 4 N=24 An Investigator Initiated, Within-Subject, Proof of Concept Study to Assess the Efficacy and Safety of Voltaren Gel in Subjects With DOMS
Pain · Delayed Onset Muscle Soreness
Primary: Mean Reduction in SPID Scores of DOMS on Walking Over 24 Hours — 34.87; 23.62 units on a scale — p=0.0324
Phase 4 N=240 Orphenadrine and Methocarbamol for LBP
Low Back Pain
Primary: Functional Impairment as Measured on the Roland Morris Disability Questionnaire — 10.9; 9.4; 8.1 units on a scale
N/A N=38 Investigation of Trunk Muscle Size and Function in Older Adults With Chronic Low Back Pain
Low Back Pain
Primary: Difference in Percent Change From Baseline in L4 Paraspinal Cross-Sectional Area Asymmetry at 6 Weeks Between Intervention Arms — 0; -17.6 % change — p=1.000
N/A N=99 Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise
Stroke · Inflammation
Primary: Cardiovascular Fitness (VO2 Peak) — 15.9; 16.6; 21.3; 17.5 ml/kg/min — p=0.001
N/A N=62 Repetitive Transcranial Magnetic Stimulation for Musculoskeletal Pain in Patients With Parkinson's Disease
Parkinson's Disease · Musculoskeletal Pain · Repetitive Transcranial Magnetic Stimulation
Primary: Change From Baseline Over 2 Months (Group by Time Interaction) in Modified KING'S PD Pain Scale Domain 1 — 12.41; 13.64; 9.96; 14.71 units on a scale
Phase 3 N=180 Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin
Neck Pain · Back Pain · Spasm
Primary: Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Day 3 of Treatment — 20.0; 28.9; 60.0; 46.7 percentage of participants — p=0.6179
Phase 2 N=4 Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease
Charcot Marie Tooth Disease
Primary: Number of Participants With a Decrease in Cramp Duration — 2; 0 participants
N/A N=33 Low Intensity Ultrasound Therapy for Upper Back Pain Relief
Muscle Spasm
Primary: Pain on the Numeric Rating Scale (NRS) — 5.60; 5.44; 3.54; 4.58 units on a scale
N/A N=34 Exercise-induced Hypoalgesia After Comparative Forms of Exercise
Pain
Primary: Change in Pain Intensity Ratings (0-100 Pain Scale) — 33.5; 46.2; 40.2 scores on a scale
Phase 3 N=300 The Effect of Pretreatment With Roc on Succinylcholine Myalgias
Myalgia
Primary: Myalgias Perceived at 3 Hours — 81; 83; 83; 15 Participants
Phase 2 N=56 Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain
Neuralgia · Myalgia
Primary: Neuromuscular Symptoms — 36.5; 43.5; 28.5; 32.7 score on a scale — p=<0.01
Phase 3 N=299 S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy
Breast Cancer · Musculoskeletal Complications · Pain
Primary: Average Joint Pain According to BPI-SF — 2.9; 3.5 units on a scale — p=0.0002
N/A N=40 Assessment of the Acute Effect of Cycling Practice in Lumbar and Thigh Muscles
Physical Endurance · Muscle Fatigue · Musculoskeletal Pain
Primary: Low Back Pain Perception (LBPP) — 1; 0.8; 3.4; 3.3 units on a scale